Executive Interview: Leo's Gitte Aabo Talks New Products, Business Change
This article was originally published in Scrip
Executive Summary
Denmark's dermatology-focused Leo Pharma has a new product for actinic keratosis in Phase III clinical studies and several investigational products in Phase II, potential new drugs that could continue a turnaround in business activity that just days ago included completion of the purchase of Astellas's dermatology portfolio, and over the past 12 months has seen top management reorganized and digital health and open innovation embraced.